Equities analysts expect BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to post sales of $25.10 million for the current fiscal quarter, Zacks reports. Five analysts have made estimates for BioDelivery Sciences International’s earnings, with estimates ranging from $23.99 million to $27.30 million. BioDelivery Sciences International posted sales of $12.18 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 106.1%. The firm is expected to announce its next quarterly earnings report on Thursday, August 8th.
On average, analysts expect that BioDelivery Sciences International will report full year sales of $101.51 million for the current year, with estimates ranging from $97.66 million to $107.25 million. For the next financial year, analysts anticipate that the company will report sales of $145.36 million, with estimates ranging from $135.60 million to $153.34 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that that provide coverage for BioDelivery Sciences International.
BioDelivery Sciences International (NASDAQ:BDSI) last issued its earnings results on Monday, May 6th. The specialty pharmaceutical company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.03. BioDelivery Sciences International had a negative return on equity of 43.40% and a negative net margin of 42.09%. The company had revenue of $19.77 million during the quarter, compared to the consensus estimate of $19.60 million.
BDSI stock traded down $0.04 during midday trading on Monday, reaching $4.96. The company had a trading volume of 961,948 shares, compared to its average volume of 1,050,251. The company has a quick ratio of 2.82, a current ratio of 2.88 and a debt-to-equity ratio of 1.90. BioDelivery Sciences International has a fifty-two week low of $1.70 and a fifty-two week high of $5.37. The company has a market cap of $433.60 million, a P/E ratio of -6.79 and a beta of 0.41.
In other news, Director Francis E. Odonnell, Jr. sold 23,000 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $5.07, for a total transaction of $116,610.00. Following the completion of the transaction, the director now directly owns 544,187 shares in the company, valued at $2,759,028.09. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Herm Cukier sold 30,285 shares of the business’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $5.07, for a total value of $153,544.95. Following the transaction, the chief executive officer now owns 66,666 shares of the company’s stock, valued at $337,996.62. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,078,335 shares of company stock valued at $10,396,895. Insiders own 13.26% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Advisor Group Inc. boosted its position in shares of BioDelivery Sciences International by 56.3% during the fourth quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock worth $40,000 after buying an additional 3,943 shares during the period. First Allied Advisory Services Inc. acquired a new position in shares of BioDelivery Sciences International during the first quarter worth approximately $58,000. Means Investment CO. Inc. acquired a new position in shares of BioDelivery Sciences International during the first quarter worth approximately $59,000. Close Asset Management Ltd boosted its position in shares of BioDelivery Sciences International by 1,340.0% during the first quarter. Close Asset Management Ltd now owns 18,000 shares of the specialty pharmaceutical company’s stock worth $95,000 after buying an additional 16,750 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in shares of BioDelivery Sciences International during the fourth quarter worth approximately $147,000. Institutional investors and hedge funds own 56.96% of the company’s stock.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Further Reading: How to read a candlestick chart
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.